Fennec Pharmaceuticals Inc (FRX : TSX)
Common Stock
$12.82
CAD
+0.13 (1.02%)
Last updated: 2026-06-22
FRX
Fennec Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
+1.02%
1 Week
+1.02%
1 Month
-6.36%
YTD
+23.15%
Key Statistics
Market Cap
$440.81M
52W High
$14.24
52W Low
$7.59
P/E Ratio
-
50 Day MA
$11.15
200 Day MA
$11.11
Beta
1.08
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $12.82 | $12.82 | $12.82 | $12.82 | $12.82 | 124 |
| 6/19/2026 | $12.69 | $12.69 | $12.69 | $12.69 | $12.69 | 0 |
| 6/18/2026 | $12.63 | $12.69 | $12.63 | $12.69 | $12.69 | 610 |
| 6/17/2026 | $12.60 | $12.96 | $12.60 | $12.85 | $12.85 | 904 |
| 6/16/2026 | $12.69 | $12.69 | $12.69 | $12.69 | $12.69 | 0 |
| 6/15/2026 | $12.69 | $12.69 | $12.69 | $12.69 | $12.69 | 1,943 |
| 6/12/2026 | $12.40 | $12.40 | $12.40 | $12.40 | $12.40 | 0 |
| 6/11/2026 | $12.40 | $12.40 | $12.40 | $12.40 | $12.40 | 0 |
| 6/10/2026 | $11.62 | $12.40 | $11.62 | $12.40 | $12.40 | 1,357 |
| 6/8/2026 | $12.44 | $12.44 | $12.44 | $12.44 | $12.44 | 519 |
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 629.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$93.57
+629.9% Upside
Current Price
C$12.82
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
97.1%
Annualized
90-Day Vol
87.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$13.61 | C$9.73 – C$19.02 |
| 60 trading days | C$14.44 | C$8.99 – C$23.19 |
| 90 trading days | C$15.33 | C$8.58 – C$27.38 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Financials
- Revenue (TTM)
- $51.00M
- EBITDA
- $-5.49M
- Profit Margin
- -16.42%
- ROE (TTM)
- -52.68%
- EPS (Diluted)
- -0.41
- Book Value
- 1.51
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About FRX
Articles Featuring FRX.TO
Latest articles and analysis covering FRX.TO
Why Fennec Pharmaceuticals Inc stock is skyrocketing today
Fennec Pharmaceuticals Inc has seen a notable 13.10% increase in its stock price, closing at CA$14.50. This surge follows the company's impressive financial results and growing demand for its PEDMARK® product.
Why Fennec Pharmaceuticals Inc stock is tanking today
Fennec Pharmaceuticals Inc's stock has dipped 1.25% today, prompting investors to reassess the company's market position and future outlook.
Why Fennec Pharmaceuticals Inc stock is tanking today
Fennec Pharmaceuticals Inc. (FRX.TO) is experiencing a downturn today, with shares falling 1.25%. This decline highlights the company's ongoing challenges in attracting investor interest despite recent positive developments.
Why Fennec Pharmaceuticals Inc stock is gaining today
Fennec Pharmaceuticals Inc (FRX.TO) has gained 1.26% in the last trading session, closing at CA$12.85. This uptick comes as the company reported impressive revenue growth, drawing investor interest.
Why Fennec Pharmaceuticals Inc stock is rising today
Fennec Pharmaceuticals Inc has seen a positive uptick in its stock price, closing at CA$12.69 after a 2.34% gain. This rise is fueled by promising developments in its clinical research and a significant increase in revenues, showcasing the company's potential for future growth.
Why Fennec Pharmaceuticals Inc stock is sliding today
Fennec Pharmaceuticals Inc's stock slid 2.20% today, closing at CA$12.44. This decline raises concerns about the company's financial stability and future growth prospects.
10 Best Canadian Biotech Stocks (Jun 2026)
Biotech has been one of the most promising engines of innovation in the field of healthcare and medicine. Consequently, it's also an avenue where a lot of big money is moving in (institutional investors, government funding, etc.). The global biotech market size is expected to reach a trillion dollar
![10 Best Canadian Biotech Stocks ([currentmonthyear])](https://lhajohzwizrsjmumhpjg.supabase.co/storage/v1/object/public/wealth-awesome/site-media/best-canadian-biotech-stocks_8-1.jpg)